The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology—multiple myeloma. V.2.2009. http://www.nccn.org. Accessed April 11, 2009.
2.
PalumboA., BringhenS., LiberatiA.M.Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood.2008; 112(8): 3107–3114.
3.
WijermansP., SchaafsmaM., Van NordenY.Melphalan + prednisone vs melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch Cooperative Group Hovon [abstract]. Haematologica.2008; 93(s1): 178.
4.
GulbrandsenN., WaageA., GimsingP.A randomised placebo controlled study with melphalan/prednisone vs melphalan/prednisone/thalidomide: quality of life and toxicity [abstract]. Haematologica.2008; 93(s1): 84.
5.
HulinC., FaconT., RodonP.Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥ 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01 [abstract]. Blood.2007; 110: abstract 75.
6.
FaconT., MaryJ.Y., HulinC.Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomized trial. Lancet.2007; 370(9594): 1209–1218.
7.
PalumboA., BringhenS., CaravitoT.Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: a randomised controlled trial. Lancet.2006; 367(9513): 825–831.
8.
PalumboA., BertolaA., MustoP.Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer.2005; 104(7): 1428–1433.
9.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
10.
National Comprehensive Cancer Network.NCCN clinical practice guidelines—antiemesis. V.3.2009. http://www.nccn.org. Accessed April 16, 2009.
11.
KrisM.G., HeskethP.J., SomerfieldM.R.American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
SmithT.J., KhatcheressianJ., LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
17.
National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology—myeloid growth factors. V.1.2009. http://www.nccn.org. Accessed April 16, 2009.
18.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
19.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–405.
20.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
21.
PalumboA., RusC., ZeldisJ.B., RodeghieroF., BoccadoroM.Enoxapirin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost.2006; 4(8): 1842–1845.
22.
DimopoulosM.A., Eleutherakis-PapaiakovouV.Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med.2004; 117(7): 508–515.
23.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
CarlsonK., HjorthM., KnudsenL.M.Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure—a retrospective analysis and recommendations for dose adjustment. Br J Haematol.2005; 128(5): 631–635.
26.
ErikssonT., HöglundP., TuressonI.Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol.2003; 55(12): 1701–1706.
27.
FloydJ., MirzaI., Sachs, PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
28.
SanoH.S., SolimandoD.A., WaddellJ.A.Melphalan and prednisone (MP) regimen for multiple myeloma. Hosp Pharm.2004; 39(4): 320–327.
